184 related articles for article (PubMed ID: 38216779)
1. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
2. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.
Zhang M; Ye J; Xie Z; Yan Y; Wang J; Chen X
Bioconjug Chem; 2021 Sep; 32(9):2108-2116. PubMed ID: 34486879
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
5. A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.
Uehara T; Yokoyama M; Suzuki H; Hanaoka H; Arano Y
Clin Cancer Res; 2018 Jul; 24(14):3309-3316. PubMed ID: 29666303
[No Abstract] [Full Text] [Related]
6. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
[TBL] [Abstract][Full Text] [Related]
7. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
8. Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.
Zhang M; Ye J; Xie Z; Wang Y; Ma W; Kang F; Yang W; Wang J; Chen X
Mol Pharm; 2022 May; 19(5):1548-1556. PubMed ID: 35357154
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
10. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with
Tolmachev V; Yim CB; Rajander J; Perols A; Karlström AE; Haaparanta-Solin M; Grönroos TJ; Solin O; Orlova A
Contrast Media Mol Imaging; 2017; 2017():8565802. PubMed ID: 29097939
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
14. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
15. Homodimeric peptide radiotracer [
Chen X; Zhang Z; Wang L; Zhang J; Zhao T; Cai J; Dang Y; Guo R; Liu R; Zhou Y; Wei R; Lou X; Xia F; Ma D; Li F; Dai J; Li F; Xi L
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2338-2352. PubMed ID: 38411667
[TBL] [Abstract][Full Text] [Related]
16. Dual MVK cleavable linkers effectively reduce renal retention of
Valpreda G; Trachsel B; Vogel V; Schibli R; Mu L; Behe M
Bioorg Med Chem; 2022 Nov; 73():117040. PubMed ID: 36202066
[TBL] [Abstract][Full Text] [Related]
17. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
18. Comparison of renal clearance of [
Liu J; Guo X; Wen L; Wang L; Liu F; Song G; Zhu H; Zhou N; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2775-2786. PubMed ID: 37093312
[TBL] [Abstract][Full Text] [Related]
19. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]